Faruqi & Faruqi, LLP Announces Shareholder Investigation Related to the Acquisition of Orthovita, Inc. - VITA

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Orthovita, Inc. (“Orthovita” or the “Company”) (NasdaqGM: VITA) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Stryker Corp. (NYSE: SYK) for about $304 million in cash. The proposed transaction offers Orthovita shareholders $3.85 per share. According to Yahoo! Finance, at least one financial analyst has a price target of $4 for Orthovita.

Request more information now by clicking here: www.faruqilaw.com/VITA

Whether the Orthovita’s Board of Directors breached their fiduciary duties to Orthovita’s stockholders by failing to conduct an adequate and fair sales process to sell the Company prior to agreeing to this proposed transaction, whether the proposed transaction undervalues Orthovita’s shares and by how much this proposed transaction undervalues the Company to the detriment of Orthovita shareholders are the key focus of this investigation.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.

If you own common stock in Orthovita and wish to obtain additional information, please visit us at www.faruqilaw.com/VITA or contact Juan E. Monteverde, Esq. either via e-mail at [e-mail] or by telephone at [phone] or [phone].

Attorney Advertising. (C) 2011 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.